The company is taking adequate steps to ensure that our tests perform as expected
Roche Diagnostics has announced that based on company’s global surveillance team’s in silico (computer-based) analyses, the cobas® SARS-CoV-2 is predicted to detect all variants including the Omicron variant (including sub-lineages BA.1 and BA.2).
The company’s statement says, “Based on our assay design, no impact of the variants including Omicron is expected on the Elecsys® Anti-SARS-CoV-2 and Elecsys® SARS-CoV-2 Antigen assays. As new variant strains emerge, we are swiftly taking adequate steps to ensure that our tests perform as expected.”
According to Narendra Varde, Managing Director, Roche Diagnostics India & Neighbouring Markets said, “We continue to monitor the evolution of SARS-CoV-2 variants and remain committed to providing laboratories with high-quality molecular and serology testing solutions that aid in diagnosing affected patients. Our cobas® SARS-CoV-2 assay has been used extensively in the country during the pandemic and continues to remain reliable and useful with the emerging Omicron variant.”